-$0.25 EPS Expected for Jounce Therapeutics, Inc. (JNCE) This Quarter
Wall Street analysts predict that Jounce Therapeutics, Inc. (NASDAQ:JNCE) will report ($0.25) earnings per share for the current quarter, Zacks reports. Two analysts have provided estimates for Jounce Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.45). The firm is scheduled to announce its next quarterly earnings results on Wednesday, November 8th.
On average, analysts expect that Jounce Therapeutics will report full year earnings of ($0.73) per share for the current year, with EPS estimates ranging from ($1.06) to ($0.50). For the next financial year, analysts forecast that the business will report earnings of ($1.47) per share, with EPS estimates ranging from ($1.58) to ($1.37). Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Jounce Therapeutics.
Jounce Therapeutics (NASDAQ:JNCE) last issued its quarterly earnings data on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $20.29 million for the quarter, compared to analyst estimates of $19.94 million. During the same period in the previous year, the business earned ($7.23) EPS.
Several equities research analysts have recently commented on the company. Zacks Investment Research cut Jounce Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Robert W. Baird restated a “buy” rating and set a $30.00 price target on shares of Jounce Therapeutics in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $23.67.
Several institutional investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new position in Jounce Therapeutics in the first quarter worth $212,000. TIAA CREF Investment Management LLC purchased a new position in Jounce Therapeutics in the first quarter worth $229,000. Teachers Advisors LLC raised its position in Jounce Therapeutics by 26.4% in the second quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares in the last quarter. ARK Investment Management LLC raised its position in Jounce Therapeutics by 558.9% in the second quarter. ARK Investment Management LLC now owns 11,932 shares of the company’s stock worth $167,000 after acquiring an additional 10,121 shares in the last quarter. Finally, Nationwide Fund Advisors raised its position in Jounce Therapeutics by 203.3% in the second quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after acquiring an additional 8,007 shares in the last quarter. Institutional investors and hedge funds own 44.11% of the company’s stock.
About Jounce Therapeutics
Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.